Commonwealth Equity Services LLC Has $272,000 Stake in Celcuity Inc. (NASDAQ:CELC)

Commonwealth Equity Services LLC increased its stake in shares of Celcuity Inc. (NASDAQ:CELC) by 9.9% during the second quarter, HoldingsChannel reports. The fund owned 16,624 shares of the company’s stock after buying an additional 1,500 shares during the period. Commonwealth Equity Services LLC’s holdings in Celcuity were worth $272,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Bank of New York Mellon Corp raised its holdings in shares of Celcuity by 42.7% during the second quarter. Bank of New York Mellon Corp now owns 66,256 shares of the company’s stock worth $1,085,000 after acquiring an additional 19,811 shares during the period. Hennion & Walsh Asset Management Inc. acquired a new stake in Celcuity in the 2nd quarter valued at $888,000. Wealth Enhancement Advisory Services LLC increased its stake in Celcuity by 7.8% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock valued at $361,000 after buying an additional 1,600 shares during the last quarter. Baker BROS. Advisors LP increased its stake in Celcuity by 189.9% in the 1st quarter. Baker BROS. Advisors LP now owns 1,552,478 shares of the company’s stock valued at $33,534,000 after buying an additional 1,017,000 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Celcuity in the 1st quarter valued at $3,545,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have issued reports on CELC shares. Stifel Nicolaus lowered their price target on shares of Celcuity from $40.00 to $39.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th. Lifesci Capital started coverage on shares of Celcuity in a research note on Monday, August 26th. They issued an “outperform” rating and a $27.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Celcuity in a research note on Thursday, August 15th. Leerink Partners initiated coverage on shares of Celcuity in a research report on Monday, July 22nd. They issued an “outperform” rating and a $29.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Celcuity in a research report on Thursday, August 15th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $28.67.

Celcuity Stock Performance

Shares of CELC opened at $14.28 on Wednesday. The firm has a 50-day moving average of $16.48 and a 200-day moving average of $16.82. Celcuity Inc. has a one year low of $8.39 and a one year high of $22.19. The company has a market cap of $501.24 million, a PE ratio of -5.14 and a beta of 0.76. The company has a debt-to-equity ratio of 0.54, a current ratio of 14.95 and a quick ratio of 14.95.

Celcuity (NASDAQ:CELC) last announced its earnings results on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same quarter in the prior year, the company posted ($0.66) EPS. As a group, equities analysts forecast that Celcuity Inc. will post -2.54 earnings per share for the current year.

Celcuity Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.